We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current APNHY market cap is 4.17B. The company's latest EPS is ZAR 9.8978 and P/E is 1.24.
| Year End 30 June 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| ZAR (R) | ZAR (R) | ZAR (R) | ZAR (R) | ZAR (R) | |
| Total Revenue | 40.54B | 39.71B | 38.61B | 40.71B | 44.71B |
| Operating Income | 8.18B | 7.76B | 7.83B | 8.77B | 7.92B |
| Net Income | 4.66B | 4.81B | 6.49B | 5.23B | 4.4B |
| Year End 30 June 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| ZAR (R) | ZAR (R) | ZAR (R) | ZAR (R) | ZAR (R) | |
| Total Assets | 133.17B | 109.68B | 111.38B | 134.28B | 139.16B |
| Total Liabilities | 63.95B | 44.06B | 40.43B | 48.05B | 54.29B |
| Total Equity | 69.22B | 65.63B | 70.94B | 86.24B | 84.86B |
| Year End 30 June 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| ZAR (R) | ZAR (R) | ZAR (R) | ZAR (R) | ZAR (R) | |
| Operating | 8.26B | 6.83B | 5.37B | 5.52B | 6.23B |
| Investing | 1.62B | 9.76B | -2.16B | -3.42B | -9.47B |
| Financing | -11.47B | -15.65B | -4.68B | -420M | 3.62B |
| Market Cap | 4.17B |
| Price to Earnings Ratio | 1.24 |
| Price to Sales Ratio | 0.12 |
| Price to Cash Ratio | 0.44 |
| Price to Book Ratio | 0.06 |
| Dividend Yield | 2.63% |
| Shares Outstanding | 444.95M |
| Average Volume (1 week) | 2.03k |
| Average Volume (1 Month) | 892 |
| 52 Week Change | -12.36% |
| 52 Week High | 13.685 |
| 52 Week Low | 8.93 |
| Spread (Intraday) | 0 (0%) |
| Company Name | Aspen Pharmacare Holdings PLC (PK) |
| Address |
building number 8 johannesburg, gauteng 2052 |
| Website | https://www.aspenpharma.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
